<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-61065" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Euglycemic Diabetic Ketoacidosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Plewa</surname>
            <given-names>Michael C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bryant</surname>
            <given-names>Michael</given-names>
          </name>
          <aff>Mercy St. Vincent Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>King-Thiele</surname>
            <given-names>Robin</given-names>
          </name>
          <aff>Campbell</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Plewa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Bryant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robin King-Thiele declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-61065.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Euglycemic diabetic ketoacidosis (EDKA) is an uncommon diabetic complication associated with several risk factors such as fasting, surgery, pregnancy, and now the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors. EDKA is primarily related to an imbalance between insulin and counter-regulatory hormones, with an elevated glucagon/insulin ratio. EDKA can lead to serious complications, including significant dehydration, if not recognized early and treated appropriately with fluids, dextrose, and insulin. This educational activity reviews the diagnosis and treatment of EDKA and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the diagnostic criteria for euglycemic diabetic ketoacidosis.</p></list-item><list-item><p>Assess&#x000a0;the pathophysiology involved in euglycemic diabetic ketoacidosis.</p></list-item><list-item><p>Identify the associated risk factors for patients relative to euglycemic diabetic ketoacidosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=61065&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=61065">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-61065.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Euglycemic diabetic ketoacidosis (DKA, EDKA) is a clinical syndrome occurring both in type 1 (T1DM) and type 2 (T2DM) diabetes mellitus characterized by euglycemia (blood glucose less than 250 mg/dL) in the presence of severe metabolic acidosis (arterial pH less than 7.3, serum bicarbonate less than 18 mEq/L) and ketonemia. DKA is&#x000a0;1 of the most severe and life-threatening complications of diabetes mellitus and can be seen in a variety of conditions. However, the incidence of EDKA has grown with the introduction of sodium-glucose transporter 2 (SGLT2) inhibitors.<xref ref-type="bibr" rid="article-61065.r1">[1]</xref> It also presents a diagnostic challenge for physicians due to the variety of etiologies and normal blood glucose levels, often resulting in delayed diagnosis.<xref ref-type="bibr" rid="article-61065.r2">[2]</xref><xref ref-type="bibr" rid="article-61065.r3">[3]</xref><xref ref-type="bibr" rid="article-61065.r4">[4]</xref></p>
      </sec>
      <sec id="article-61065.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are many known causes of EDKA in patients with diabetes. The overall mechanism is based on a general state of starvation, resulting in ketosis while maintaining normoglycemia. Therefore, conditions like anorexia, gastroparesis, fasting, use of a ketogenic diet, and alcohol use disorder can lead to states of carbohydrate starvation and subsequent ketosis. Additional triggers for EDKA include pregnancy,&#x000a0;pancreatitis, glycogen storage disorders, surgery, infection, cocaine toxicity, cirrhosis, and insulin pump use.<xref ref-type="bibr" rid="article-61065.r5">[5]</xref><xref ref-type="bibr" rid="article-61065.r6">[6]</xref><xref ref-type="bibr" rid="article-61065.r7">[7]</xref> T1DM who underwent bariatric surgery patients experience DKA in over 20% of postoperative cases and may be especially prone to EDKA.<xref ref-type="bibr" rid="article-61065.r8">[8]</xref></p>
        <p>The newer oral antidiabetic medication category of SGLT2 inhibitors, including canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, can also directly result in EDKA.<xref ref-type="bibr" rid="article-61065.r2">[2]</xref><xref ref-type="bibr" rid="article-61065.r3">[3]</xref><xref ref-type="bibr" rid="article-61065.r9">[9]</xref><xref ref-type="bibr" rid="article-61065.r10">[10]</xref><xref ref-type="bibr" rid="article-61065.r11">[11]</xref><xref ref-type="bibr" rid="article-61065.r12">[12]</xref><xref ref-type="bibr" rid="article-61065.r13">[13]</xref>&#x000a0;EDKA may be more common in patients with diabetes on SGLT2 inhibitors with lower body mass index and decreased glycogen stores.<xref ref-type="bibr" rid="article-61065.r1">[1]</xref>&#x000a0;Episodes can be triggered by surgery, infection, trauma, a major illness, reduced food intake, persistent vomiting, gastroparesis, dehydration, and reduced insulin dosages.<xref ref-type="bibr" rid="article-61065.r14">[14]</xref>&#x000a0;On rare occasions, a patient in DKA may receive enough extra insulin to bring the blood sugar under 250 mg/dL.</p>
      </sec>
      <sec id="article-61065.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately 2.6% to 3.2% of DKA admissions are euglycemic.<xref ref-type="bibr" rid="article-61065.r9">[9]</xref><xref ref-type="bibr" rid="article-61065.r15">[15]</xref> DKA-associated with the use of SGLT2 inhibitors has rates ranging from 0.16 to 0.76 events per 1000 patient-years in patients with type 2 diabetes. Blau et al estimate that the SGLT2 inhibitors increase the risk of DKA in T2D patients by 7-fold.<xref ref-type="bibr" rid="article-61065.r16">[16]</xref>&#x000a0;Erondu et al estimate an overall incidence of DKA from SGLT2 inhibitor use of approximately 0.1%.<xref ref-type="bibr" rid="article-61065.r17">[17]</xref>&#x000a0;Data on patients with type 1 diabetes who presented with DKA associated with SGLT2 inhibitors showed rates varying from 5 to 12%; however, euglycemia was not present in all cases.<xref ref-type="bibr" rid="article-61065.r10">[10]</xref>&#x000a0;SGLT2 inhibitors are not approved for use in patients with type 1 diabetes. Data associated with other causes of&#x000a0;EDKA is scarce.</p>
      </sec>
      <sec id="article-61065.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The underlying mechanism of EDKA is secondary to a carbohydrate deficit resulting in generalized decreased serum insulin and excess counter-regulatory hormones like glucagon, epinephrine, and cortisol. The increased glucagon/insulin ratio leads to increased lipolysis, increased free fatty acids, and ketoacidosis.<xref ref-type="bibr" rid="article-61065.r2">[2]</xref><xref ref-type="bibr" rid="article-61065.r9">[9]</xref><xref ref-type="bibr" rid="article-61065.r12">[12]</xref> Ketone body production in EDKA is similar to DKA with acetoacetic acid, beta-hydroxybutyric acid (after acetoacetic acid reduction), and acetone (after acetoacetic acid decarboxylation). The resulting anion gap metabolic acidosis triggers respiratory compensation and the sensation of dyspnea, as well as nausea, anorexia, and vomiting. Volume depletion resulting from decreased oral intake, vomiting, and osmotic diuresis from glucosuria further exacerbates glucagon, cortisol, and epinephrine elevations, worsening lipolysis and ketogenesis.&#x000a0;Additionally, decreased gluconeogenesis by the liver occurs in fasting where hepatic glycogen is already depleted, or increased glucosuria by the kidneys contributes to EDKA.<xref ref-type="bibr" rid="article-61065.r3">[3]</xref>&#x000a0;Often, insulin-using patients do not recognize their symptoms as DKA because serum glucose is not elevated, and they may maintain or decrease their insulin dose.<xref ref-type="bibr" rid="article-61065.r1">[1]</xref>&#x000a0;If insulin dosing is adequate for glucose levels, it prevents gluconeogenesis, resulting in euglycemia. EDKA can be considered a &#x0201c;partially treated DKA&#x0201d; in this setting.<xref ref-type="bibr" rid="article-61065.r9">[9]</xref></p>
        <p>SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) are a newer class of antidiabetic drugs that increase the risk of EDKA unrelated to the duration of exposure.<xref ref-type="bibr" rid="article-61065.r16">[16]</xref><xref ref-type="bibr" rid="article-61065.r18">[18]</xref><xref ref-type="bibr" rid="article-61065.r19">[19]</xref>&#x000a0;The use of SGLT2 inhibitors in T1DM is not recommended by the U.S. Food and Drug Administration and is discouraged because the risk of ketone-associated effects can be as high as 9%.<xref ref-type="bibr" rid="article-61065.r1">[1]</xref><xref ref-type="bibr" rid="article-61065.r20">[20]</xref><xref ref-type="bibr" rid="article-61065.r21">[21]</xref> The risk of EDKA among T2DM patients on SGLT2 inhibitors may be higher in patients with beta-cell insufficiency and perhaps predict those at greater risk for evolving to T1DM.<xref ref-type="bibr" rid="article-61065.r20">[20]</xref> The mechanism of action of SGLT2 inhibitors is to enhance excretion and block reabsorption of filtered glucose from the proximal convoluted tubule.<xref ref-type="bibr" rid="article-61065.r22">[22]</xref>&#x000a0;The loss of urinary glucose again creates a state of carbohydrate starvation and volume depletion, increasing the glucagon/insulin ratio and resulting in severe dehydration and ketosis.<xref ref-type="bibr" rid="article-61065.r1">[1]</xref></p>
        <p>Additionally, SGLT2 inhibitors have been found to directly stimulate the release of glucagon from the pancreas, further worsening the glucagon/insulin imbalance and suppressing the removal of beta-hydroxybutyrate and acetoacetate by the kidneys.<xref ref-type="bibr" rid="article-61065.r22">[22]</xref><xref ref-type="bibr" rid="article-61065.r23">[23]</xref><xref ref-type="bibr" rid="article-61065.r24">[24]</xref> Euglycemia is maintained due to the loss of urinary glucose&#x000a0;<xref ref-type="bibr" rid="article-61065.r2">[2]</xref><xref ref-type="bibr" rid="article-61065.r9">[9]</xref><xref ref-type="bibr" rid="article-61065.r10">[10]</xref><xref ref-type="bibr" rid="article-61065.r25">[25]</xref><xref ref-type="bibr" rid="article-61065.r26">[26]</xref>&#x000a0;and SGLT2 inhibitor-triggered hypoinsulinemia.<xref ref-type="bibr" rid="article-61065.r27">[27]</xref>&#x000a0;SGLT2 inhibitors also increase ketone reabsorption, such that ketosis is common in patients taking SGLT2 inhibitors after a trigger such as pregnancy, alcohol, surgery, infection, or starvation.<xref ref-type="bibr" rid="article-61065.r9">[9]</xref><xref ref-type="bibr" rid="article-61065.r18">[18]</xref>&#x000a0;Pregnancy is a risk factor for EDKA because of the physiologic state of hypoinsulinemia and increased starvation. Increased levels of cortisol and placental lactogen result in insulin resistance, and episodes of vomiting or fasting can lead to exaggerated starvation ketosis.<xref ref-type="bibr" rid="article-61065.r28">[28]</xref> Respiratory alkalosis leading to bicarbonate loss in the urine exacerbates the acidosis.<xref ref-type="bibr" rid="article-61065.r29">[29]</xref> These factors, taken together, can result in starvation, euglycemia, and ketoacidosis by the previous mechanisms described.<xref ref-type="bibr" rid="article-61065.r2">[2]</xref></p>
        <p>Alcoholic ketoacidosis may have a similar presentation to EDKA, with anorexia, vomiting, dyspnea, and significant anion gap metabolic acidosis and ketonemia. Some consider alcoholic ketoacidosis a subtype of EDKA, and both are associated with increased glucagon/insulin ratio.<xref ref-type="bibr" rid="article-61065.r1">[1]</xref><xref ref-type="bibr" rid="article-61065.r9">[9]</xref><xref ref-type="bibr" rid="article-61065.r15">[15]</xref> The differentiating factors are that alcoholic ketoacidosis patients do not have diabetes or use diabetic medications and are more commonly present with hypoglycemia or after a severe alcohol binge.<xref ref-type="bibr" rid="article-61065.r26">[26]</xref> Similarly, excessive alcohol consumption in a person with diabetes can destroy pancreatic beta cells, decrease gluconeogenesis, and decrease glycogen stores. Coupled with vomiting and carbohydrate starvation, it results in accelerated lipolysis, ketoacidosis, and EDKA.<xref ref-type="bibr" rid="article-61065.r2">[2]</xref><xref ref-type="bibr" rid="article-61065.r9">[9]</xref></p>
      </sec>
      <sec id="article-61065.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Signs and symptoms vary on a case-by-case basis but are similar in presentation&#x000a0;to hyperglycemic DKA, although perhaps without polyuria, polydipsia, or severe mental status changes. EDKA patients can present with nausea, vomiting, shortness of breath, generalized malaise, lethargy, loss of appetite, fatigue, or abdominal pain. Patients may not have polydipsia or polyuria since serum glucose is normal. The onset can be more insidious compared to hyperglycemic DKA due to the mechanism of subacute starvation required to induce ketosis and dehydration. There may or may not be an inciting infection&#x000a0;or stressors, such as pregnancy, surgery, pancreatitis, alcohol use, or fasting.<xref ref-type="bibr" rid="article-61065.r30">[30]</xref>&#x000a0;Patients may present with deep, rapid breathing, known as Kussmaul respiration, which represents respiratory compensation for severe metabolic acidosis. They may have a fruity odor to their breath due to the loss of acetone. Tachycardia, hypotension, altered mentation, increased skin turgor, and delayed capillary refill are all signs of total body fluid loss. In severe cases, severe dehydration and metabolic derangement can lead to hypovolemic shock, lethargy, respiratory failure, coma, and death.</p>
      </sec>
      <sec id="article-61065.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>An ill-feeling patient with diabetes with symptoms such as malaise, dyspnea, nausea, or vomiting should undergo screening with serum pH and blood or urine ketone testing.<xref ref-type="bibr" rid="article-61065.r3">[3]</xref><xref ref-type="bibr" rid="article-61065.r31">[31]</xref><xref ref-type="bibr" rid="article-61065.r32">[32]</xref><xref ref-type="bibr" rid="article-61065.r33">[33]</xref>&#x000a0;The initial laboratory evaluation of EDKA includes basic electrolytes, glucose, calcium, magnesium, creatinine, BUN, serum and urine ketones, beta-hydroxybutyric acid, arterial or venous blood gas analysis, lactic acid, chest radiograph, and electrocardiogram. Urine screening for ketones with nitroprusside reagent does not measure beta-hydroxybutyrate but detects acetone and acetoacetate. Serum levels of beta-hydroxybutyrate are typically greater than 3 mmol/L in EDKA (normal values less than 0.5 mmol/L). Consider CBC with differential white blood cell count and blood cultures if an infection is on the differential. Serum osmolality, to assess for an osmolar gap and toxic alcohols, should be sent to rule out toxic alcohol ingestion when suspected in any patient with severe, unexplained anion gap metabolic acidosis. Close attention should be paid to the anion gap to help narrow direct diagnosis, workup, and management.</p>
        <p>As described previously, the patient has normoglycemia (capillary blood glucose less than 250 mg/dL) in the presence of metabolic acidosis (pH less than 7.3) and a total decreased serum bicarbonate (less than 18 mEq/L). Serum and urine ketones must be elevated to make the diagnosis of EDKA. Lactic acid may be elevated but should not account entirely for the elevation in the anion gap. Leukocytosis may be present in the case of a concurrent infection; however, it is nonspecific and could also be due to hemoconcentration or stress, among other causes. Potassium levels vary, but great attention should be paid to the level before starting therapy, as total body potassium is usually depleted. Hypomagnesemia and hypophosphatemia can be seen in starvation due to decreased total intake and increased losses. Mild hyponatremia may also be seen but is generally less severe than the &#x0201c;pseudo-hyponatremia&#x0201d; seen in profound hyperglycemic states.</p>
      </sec>
      <sec id="article-61065.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Initial management should be directed toward fluid resuscitation, as patients usually present as profoundly dehydrated. Begin with the administration of isotonic saline or lactated Ringer solution. The American Diabetes Association (ADA) recommends 1 to 1.5 L/hr isotonic fluids during the first 1 to 2 hours. Continuous insulin infusion should follow fluid replacement, contingent on serum potassium levels greater than 3.3 mEq/L, starting at a rate of 0.05 to 0.1 U/kg/hr. In contrast to DKA management, since serum glucose in EDKA is less than 250 mg/dL, dextrose 5% should initially be added to the fluids to avoid hypoglycemia and hasten clearance of ketosis.<xref ref-type="bibr" rid="article-61065.r34">[34]</xref> Consider increasing the amount of dextrose to 10% if ketoacidosis persists on D5%.<xref ref-type="bibr" rid="article-61065.r27">[27]</xref><xref ref-type="bibr" rid="article-61065.r35">[35]</xref><xref ref-type="bibr" rid="article-61065.r27">[27]</xref></p>
        <p>Potassium should also be carefully monitored as total body potassium levels are likely to be depleted, and IV supplementation of potassium and other electrolytes may be needed. Blood glucose levels should be checked hourly, and electrolytes should be checked every&#x000a0;4 hours at a minimum, as is the standard for treating DKA. Patients taking SGLT2 inhibitors should have these medications discontinued as soon as the diagnosis is recognized and held until recovery from the acute illness.<xref ref-type="bibr" rid="article-61065.r10">[10]</xref> Sodium bicarbonate infusions are not indicated and even use in severe acidemia of pH less than 6.9 is controversial. Patients generally require ICU admission for close hemodynamic and laboratory monitoring and frequent titration of insulin infusion.<xref ref-type="bibr" rid="article-61065.r2">[2]</xref><xref ref-type="bibr" rid="article-61065.r36">[36]</xref><xref ref-type="bibr" rid="article-61065.r37">[37]</xref>&#x000a0;Treatment with IV fluid resuscitation should continue until the anion gap closes and acidosis has resolved.</p>
      </sec>
      <sec id="article-61065.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In patients presenting with anion gap metabolic acidosis,&#x000a0;clinicians must consider a variety of&#x000a0;possibilities early on. Infections, including pneumonia, genitourinary infection, and bacteremia, must be ruled out early in the diagnostic algorithm. In patients presenting with abdominal pain, consider intraabdominal infection and pancreatitis. Consider toxic alcohol (methanol, ethylene glycol) or paraldehyde ingestion, salicylate overdose, lactic acidosis, starvation ketosis, and pregnancy in the appropriate clinical setting. Patients may have also recently administered insulin, contributing to the euglycemic presentation. The presentation is very similar to alcoholic ketoacidosis, except EDKA patients have diabetes, and&#x000a0;alcoholic ketoacidosis patients present after an alcohol binge more commonly have hypoglycemia and can be successfully resuscitated with crystalloid and dextrose without the requirement for insulin.</p>
      </sec>
      <sec id="article-61065.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most patients with EDKA recover well with prompt recognition and treatment. Delayed diagnosis and inadequate treatment, especially hydration without dextrose/insulin infusion, can lead to persistent acidosis, vomiting, and prolonged hospitalization. The prognosis is worse for small children and pregnant women. Rarely, severe cases of respiratory failure, hypovolemic shock, coma, and death. Death is rare in most EDKA cases; however, pregnant women are at greater mortality risk than the general population.</p>
      </sec>
      <sec id="article-61065.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Euglycemic DKA can result in persistent vomiting, dehydration, hypoglycemia, hypovolemic shock, respiratory failure, cerebral edema, coma, seizures, infection, thrombosis, myocardial infarction, and death.<xref ref-type="bibr" rid="article-61065.r38">[38]</xref>&#x000a0;Maternal EDKA can increase the rate of fetal (up to 9%) and maternal mortality.<xref ref-type="bibr" rid="article-61065.r39">[39]</xref><xref ref-type="bibr" rid="article-61065.r40">[40]</xref></p>
      </sec>
      <sec id="article-61065.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consider consultation with a critical care intensivist and endocrinologist for severe cases. Pregnant women suffering from EDKA benefit from involvement with obstetric and maternal-fetal medicine consultants.</p>
      </sec>
      <sec id="article-61065.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Vigilant monitoring of capillary or urine ketones by patients with diabetes, especially during episodes of nausea or illness, can diagnose EDKA before it becomes severe. Although the SGLT2 inhibitors have been shown to have extra benefits on cardiovascular and kidney health, they are not recommended to be used in managing patients with T1DM because of the high risk of EDKA.<xref ref-type="bibr" rid="article-61065.r41">[41]</xref><xref ref-type="bibr" rid="article-61065.r42">[42]</xref><xref ref-type="bibr" rid="article-61065.r43">[43]</xref></p>
      </sec>
      <sec id="article-61065.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about&#x000a0;euglycemic diabetic ketoacidosis are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Successful diagnosis depends on early screening with serum or urine ketones, even when serum glucose is normal, whenever EDKA is suspected.</p>
          </list-item>
          <list-item>
            <p>After volume expansion with crystalloid, the foundation of therapy is a combination of dextrose (5 to 10%) and insulin (0.05 to 0.1 u/kg/hr) infusion until acidosis resolves.</p>
          </list-item>
          <list-item>
            <p>Insulin infusion should not be avoided due to normal glucose levels, but it is essential to successful treatment.</p>
          </list-item>
          <list-item>
            <p>Ketosis does not resolve with intravenous crystalloid hydration alone.</p>
          </list-item>
          <list-item>
            <p>SGLT2 inhibitor treatment should be discontinued as soon as EDKA is diagnosed.</p>
          </list-item>
          <list-item>
            <p>Sodium bicarbonate infusion is not indicated.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-61065.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Euglycemic DKA is becoming more prevalent with the appearance of the new SGLT2 inhibitors. However, it is important to recognize the variety of etiologies of a potentially fatal condition. Early diagnosis and initiation of treatment can significantly improve morbidity and mortality. In patients presenting with euglycemic anion gap acidosis, great care&#x000a0;is necessary to rule out other causes, including sepsis, toxic alcohol ingestion, and alcoholic ketoacidosis, among others. The primary treatments are early IV crystalloid and prompt initiation of insulin and dextrose infusion.</p>
        <p>Treatment requires a team of interprofessional healthcare workers consisting of clinicians (MDs, DOs, NPS, or PAs), possibly including consultation with a critical care intensivist and an endocrinologist. Emergency and critical care nurses monitor patients, administer ordered treatments, and report changes to physicians to optimize treatment. The clinicians can also consult with the pharmacy regarding appropriate interventions and have them run a full medication reconciliation to check for drug interactions or agents that may contribute to EDKA. All interprofessional team members must be prepared to communicate with the rest of the team as they note any changes in patient status, including therapeutic failure. The observations must also be documented in the patient's health record so all interprofessional team members can access the same accurate patient data. In this way, appropriate corrective actions can be implemented. These interprofessional interventions are crucial to achieving better patient outcomes.</p>
      </sec>
      <sec id="article-61065.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=61065&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=61065">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/diabetes/euglycemic-diabetic-ketoacidosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=61065">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/61065/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=61065">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-61065.s17">
        <title>References</title>
        <ref id="article-61065.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Buschur</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cohan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1687</fpage>
            <page-range>1687-93</page-range>
            <pub-id pub-id-type="pmid">26078479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis: A Review.</article-title>
            <source>Curr Diabetes Rev</source>
            <year>2017</year>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-321</page-range>
            <pub-id pub-id-type="pmid">27097605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vellipuram</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bandaru</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Pradeep Raj</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma.</article-title>
            <source>Endocrinol Diabetes Metab Case Rep</source>
            <year>2017</year>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28924481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrivastava</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic diabetic ketoacidosis: A missed diagnosis.</article-title>
            <source>World J Diabetes</source>
            <year>2021</year>
            <month>May</month>
            <day>15</day>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>514</fpage>
            <page-range>514-523</page-range>
            <pub-id pub-id-type="pmid">33995841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wazir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shittu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dukhan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharief</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alansari</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic diabetic ketoacidosis in pregnancy with COVID-19: A case report and literature review.</article-title>
            <source>Clin Case Rep</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e05680</fpage>
            <pub-id pub-id-type="pmid">35414931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>RX</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XP</given-names>
              </name>
            </person-group>
            <article-title>Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy.</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-30</page-range>
            <pub-id pub-id-type="pmid">18588610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madaan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Diabetic ketoacidosis occurring with lower blood glucose levels in pregnancy: a report of two cases.</article-title>
            <source>J Reprod Med</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>57</volume>
            <issue>9-10</issue>
            <fpage>452</fpage>
            <page-range>452-5</page-range>
            <pub-id pub-id-type="pmid">23091997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowsett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krones</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Normal Blood Glucose and High Blood Ketones in a Critically Unwell Patient with T1DM Post-Bariatric Surgery: a Case&#x000a0;of Euglycemic Diabetic Ketoacidosis.</article-title>
            <source>Obes Surg</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>347</fpage>
            <page-range>347-349</page-range>
            <pub-id pub-id-type="pmid">30328578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis.</article-title>
            <source>Int J Endocrinol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>7074868</fpage>
            <pub-id pub-id-type="pmid">30369948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldenberg</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Berard</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AYY</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Yale</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.</article-title>
            <source>Clin Ther</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>2654</fpage>
            <page-range>2654-2664.e1</page-range>
            <pub-id pub-id-type="pmid">28003053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joseph</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goenka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Starvation-induced true diabetic euglycemic ketoacidosis in severe depression.</article-title>
            <source>J Gen Intern Med</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-31</page-range>
            <pub-id pub-id-type="pmid">18975036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burge</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qualls</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Schade</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Differential effects of fasting and dehydration in the pathogenesis of diabetic ketoacidosis.</article-title>
            <source>Metabolism</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-7</page-range>
            <pub-id pub-id-type="pmid">11229425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Secinaro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ciavarella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Porreca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vitacolonna</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report.</article-title>
            <source>Acta Diabetol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>59</volume>
            <issue>10</issue>
            <fpage>1391</fpage>
            <page-range>1391-1394</page-range>
            <pub-id pub-id-type="pmid">35718795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legaspi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narciso</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis Due to Gastroparesis, A Local Experience.</article-title>
            <source>J Ark Med Soc</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>112</volume>
            <issue>5</issue>
            <fpage>62</fpage>
            <page-range>62-3</page-range>
            <pub-id pub-id-type="pmid">26390536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jenkins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Close</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Krentz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nattrass</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Euglycaemic diabetic ketoacidosis: does it exist?</article-title>
            <source>Acta Diabetol</source>
            <year>1993</year>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-3</page-range>
            <pub-id pub-id-type="pmid">8180418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blau</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tella</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Rother</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">28736981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erondu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ways</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meininger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1680</fpage>
            <page-range>1680-6</page-range>
            <pub-id pub-id-type="pmid">26203064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Blau</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rother</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>SGLT2 Inhibitors May Predispose to Ketoacidosis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>100</volume>
            <issue>8</issue>
            <fpage>2849</fpage>
            <page-range>2849-52</page-range>
            <pub-id pub-id-type="pmid">26086329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somagutta</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Agadi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hange</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Batti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Emuze</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Amos-Arowoshegbe</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hanan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Pormento</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Mar</month>
            <day>03</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>e13665</fpage>
            <pub-id pub-id-type="pmid">33824816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrannini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1638</fpage>
            <page-range>1638-42</page-range>
            <pub-id pub-id-type="pmid">26294774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Thakkar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Polidori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alba</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>2258</fpage>
            <page-range>2258-65</page-range>
            <pub-id pub-id-type="pmid">26486192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pf&#x000fc;tzner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klonoff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ejskjaer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pickup</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.</article-title>
            <source>Endocrine</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>212</fpage>
            <page-range>212-216</page-range>
            <pub-id pub-id-type="pmid">28303514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kerr-Conte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gmyr</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Queniat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moerman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Th&#x000e9;venet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beaucamps</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delalleau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Malaisse</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Sener</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deprez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abderrahmani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Staels</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pattou</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.</article-title>
            <source>Nat Med</source>
            <year>2015</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-7</page-range>
            <pub-id pub-id-type="pmid">25894829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrannini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Muscelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frascerra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Broedl</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Woerle</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.</article-title>
            <source>J Clin Invest</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>499</fpage>
            <page-range>499-508</page-range>
            <pub-id pub-id-type="pmid">24463454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crespo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McConnell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wick</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis: Hidden in Plain Sight.</article-title>
            <source>Consult Pharm</source>
            <year>2016</year>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>426</fpage>
            <page-range>426-34</page-range>
            <pub-id pub-id-type="pmid">27535077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umpierrez</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concern.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>441</fpage>
            <page-range>441-442</page-range>
            <pub-id pub-id-type="pmid">28621337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bader</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.</article-title>
            <source>Pak J Med Sci</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>786</fpage>
            <page-range>786-8</page-range>
            <pub-id pub-id-type="pmid">27375734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Venkatram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diaz-Fuentes</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Starvation ketoacidosis: a cause of severe anion gap metabolic acidosis in pregnancy.</article-title>
            <source>Case Rep Crit Care</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>906283</fpage>
            <pub-id pub-id-type="pmid">24963418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chapela</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature.</article-title>
            <source>Case Rep Crit Care</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>1747850</fpage>
            <pub-id pub-id-type="pmid">30364093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dass</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic DKA (euDKA) as a presentation of COVID-19.</article-title>
            <source>Clin Case Rep</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>395</fpage>
            <page-range>395-398</page-range>
            <pub-id pub-id-type="pmid">33362928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Blood Ketones: Measurement, Interpretation, Limitations, and Utility in the Management of Diabetic Ketoacidosis.</article-title>
            <source>Rev Diabet Stud</source>
            <year>2016</year>
            <season>Winter</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-225</page-range>
            <pub-id pub-id-type="pmid">28278308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Khamooshi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reyes Pinzon</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>e24016</fpage>
            <pub-id pub-id-type="pmid">35573514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandez Felix</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Madrigal Loria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arias Morales</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>e25818</fpage>
            <pub-id pub-id-type="pmid">35698468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munro</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>McCuish</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Euglycaemic diabetic ketoacidosis.</article-title>
            <source>Br Med J</source>
            <year>1973</year>
            <month>Jun</month>
            <day>09</day>
            <volume>2</volume>
            <issue>5866</issue>
            <fpage>578</fpage>
            <page-range>578-80</page-range>
            <pub-id pub-id-type="pmid">4197425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan Azman</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sukor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abu Shamsi</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kamaruddin</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>867647</fpage>
            <pub-id pub-id-type="pmid">35712244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nyenwe</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kitabchi</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management.</article-title>
            <source>Metabolism</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>507</fpage>
            <page-range>507-21</page-range>
            <pub-id pub-id-type="pmid">26975543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zughaib</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Affas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>e21768</fpage>
            <pub-id pub-id-type="pmid">35251838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Nishihata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawamatsu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Komatsu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ishimatsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Komiyama</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis.</article-title>
            <source>J Cardiol Cases</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>56</fpage>
            <page-range>56-60</page-range>
            <pub-id pub-id-type="pmid">30546697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalfr&#x000e0;</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sartore</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lapolla</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ketoacidosis in diabetic pregnancy.</article-title>
            <source>J Matern Fetal Neonatal Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>17</issue>
            <fpage>2889</fpage>
            <page-range>2889-95</page-range>
            <pub-id pub-id-type="pmid">26461169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarif</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Al Badr</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Euglycemic diabetic ketoacidosis in pregnancy.</article-title>
            <source>Saudi J Kidney Dis Transpl</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>590</fpage>
            <page-range>590-3</page-range>
            <pub-id pub-id-type="pmid">17951948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsutsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brueckmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schnee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cotton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bocchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chuquiure</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giannetti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez Juanatey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brunner-La Rocca</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pina</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Senni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seronde</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Spinar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Taddei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <collab>EMPEROR-Reduced Trial Investigators</collab>
            </person-group>
            <article-title>Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Oct</month>
            <day>08</day>
            <volume>383</volume>
            <issue>15</issue>
            <fpage>1413</fpage>
            <page-range>1413-1424</page-range>
            <pub-id pub-id-type="pmid">32865377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Inzucchi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kosiborod</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>B&#x0011b;lohl&#x000e1;vek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Diez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drozdz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duk&#x000e1;t</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Howlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Katova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitakaze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ljungman</surname>
                <given-names>CEA</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nicolau</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vinh</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Schou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tereshchenko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Docherty</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Jhund</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;strand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Langkilde</surname>
                <given-names>AM</given-names>
              </name>
              <collab>DAPA-HF Trial Committees and Investigators</collab>
            </person-group>
            <article-title>Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Nov</month>
            <day>21</day>
            <volume>381</volume>
            <issue>21</issue>
            <fpage>1995</fpage>
            <page-range>1995-2008</page-range>
            <pub-id pub-id-type="pmid">31535829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-61065.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heerspink</surname>
                <given-names>HJL</given-names>
              </name>
              <name>
                <surname>Stef&#x000e1;nsson</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Correa-Rotter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JFE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Lindberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Langkilde</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <collab>DAPA-CKD Trial Committees and Investigators</collab>
            </person-group>
            <article-title>Dapagliflozin in Patients with Chronic Kidney Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Oct</month>
            <day>08</day>
            <volume>383</volume>
            <issue>15</issue>
            <fpage>1436</fpage>
            <page-range>1436-1446</page-range>
            <pub-id pub-id-type="pmid">32970396</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
